Abstract
MicroRNAs (miRNAs) have emerged as crucial regulators of T lymphocyte survival, differentiation and function, all of which are key factors impacting the outcome of adoptive T cell-based immunotherapy. It has become increasingly clear that the adoptive transfer of memory CD8 + T cell subsets is highly correlated with objective clinical responses for patients with advanced cancer. However, it is unclear how to improve the long-term persistence of transferred CD8 + T cells using miRNAs. Here, we highlight the current advances in our understanding of the role of miRNAs in regulating the differentiation of memory CD8 + T cells. We specifically discuss the effect of miRNAs on key transcription factors, immune checkpoints and signal pathways, which contribute to the differentiation of effector and memory T cell subsets. Ultimately, miRNAs may be easily integrated into existing T cell receptor (TCR) and chimeric antigen receptor (CAR) platforms to promote adoptive T cell therapy with multiple advantages. Thus, combining T cell-based therapy with miRNAs could be considered a promising and robust strategy for cancer treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 2187-2198 |
Number of pages | 12 |
Journal | Cellular Physiology and Biochemistry |
Volume | 47 |
Issue number | 6 |
DOIs | |
State | Published - Jul 1 2018 |
Keywords
- Adoptive T cell therapy
- Memory T cells
- MicroRNAs
ASJC Scopus subject areas
- Physiology